ALK and neoplasm: Genetic or pharmacologic disruption in the NPM::ALK-ACLY signaling axis leads to impaired cell proliferation, impaired clonogenic potential, reduced tumor growth in an in vivo xenograft model, and attenuated lipid synthesis in ALK+ ALCL (42).